Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Downgrades Victoria’s Secret to Equal-Weight

Morgan Stanley analyst Kimberly Greenberger downgrades Victoria's Secret (NYSE:VSCO) from Overweight to Equal-Weight.

byBenzinga Newsdesk

August 25, 2021

1 minute read

Morgan Stanley analyst Kimberly Greenberger downgrades Victoria’s Secret (NYSE:VSCO) from Overweight to Equal-Weight.

UBS Maintains Neutral on Papa John’s International, Raises Price Target to $114

By Benzinga Newsdesk

Today, 5:58 AM

UBS analyst Dennis Geiger maintains Papa John's International (NASDAQ:PZZA) with a Neutral and raises the price target from $104 to $114.

PZZA

AMSC Pockets $23M In New Energy Power System Orders

By Akanksha Bakshi

Today, 5:58 AM

American Superconductor Corp (NASDAQ:AMSC) has received $23 million in new energy power systems orders. The orders include reactive compensation, enclosed…

AMSC

Krispy Kreme Reaffirms FY22 Guidance; Sees Adj. EPS $0.38-$0.41, Sales $1.53B-$1.56B

By Bill Haddad

Today, 5:58 AM

2022 Financial Outlook Krispy Kreme re-affirms its previous guidance for the full year 2022: Net Revenue of $1.53 billion to $1.56 billion (+11% to +13%) Organic Revenue

DNUT

EQRx’s Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings

By Vandana Singh

Today, 5:58 AM

EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-small cell lung cancer (NSCLC).

EQRX

Morgan Stanley Downgrades Victoria’s Secret to Equal-Weight

Related Posts

UBS Maintains Neutral on Papa John’s International, Raises Price Target to $114

AMSC Pockets $23M In New Energy Power System Orders

Krispy Kreme Reaffirms FY22 Guidance; Sees Adj. EPS $0.38-$0.41, Sales $1.53B-$1.56B

EQRx’s Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings